chemical

7586/10

7586/10

10 mg (also 50 mg)

167 USD

7586/10

Molnupiravir

10 mg (also 50 mg)

Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection

Antiviral Compounds

Small Molecules

98%

329.31

?utm_source=labome&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

Molnupiravir is a broad-spectrum antiviral prodrug of the nucleoside analog -D-N4-hydroxycytidine (NHC). Molnupiravir competes predominantly with CTP for incorporation; it induces lethal viral mutagenesis by increasing G to A and C to U transition mutations without inhibition of RNA synthesis in replicating coronaviruses, which prevents the development of viral resistance. In primary airway epithelial cell cultures, Molnupiravir dose-dependently inhibits SARS-CoV-2 infectious virus production; it also inhibits MERS-CoV and SARS-CoV with EC50 values in the submicromolar range. In mice infected with SARS-CoV or MERS-CoV, Molnupiravir improves pulmonary function, and reduces virus titer and body weight loss. Molnupiravir also displays in vivo efficacy against seasonal and pandemic influenza A shed virus. It is orally bioavailable.

Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection

Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection

-D-N4-hydroxycytidine-5 -isopropyl ester

C13H19N3O7

C13H19N3O7

2492423-29-5

167 USD

Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection

Store at -20░C